22 results on '"Guiu S"'
Search Results
2. 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study
3. 1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer
4. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
5. Quantification de la graisse viscérale et sous-cutanée au scanner : corrélation inter-observateur d’une technique monocoupe
6. Quantification of the visceral and subcutaneous fat by computed tomography: Interobserver correlation of a single slice technique
7. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
8. Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
9. Intérêt de l’association bévacizumab/irinotécan dans le traitement des glioblastomes. Une étude multicentrique de l’ANOCEF
10. 483P Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
11. Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef
12. 213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
13. 314P Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane
14. 104P Clinical characteristics of patients (pts) with complete response (CR) to abemaciclib-based endocrine therapy (ET) in MONARCH 2 (M2) and MONARCH 3 (M3)
15. 306P Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
16. 288PD - PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
17. 266P - Use of everolimus in advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study
18. 117P - Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial
19. 391P - Eribex: a Retrospective, International, Multicenter Study on the Efficacy and Safety of Eribuline Mesylate in Metastatic Breast Cancer
20. Analyse de la proportion de tumeurs mammaires HER2 positives, de leurs caractéristiques clinicopathologiques ainsi que de leur évolution entre 1998 et 2008. Étude mono-institutionnelle sur 2396 patientes résidant dans le seul département français couvert par un registre spécialisé
21. Abstract No. 325: Addition of Pirarubicin and Amiodarone in TACE of Unresectable Hepatocellular Carcinoma: A Pilot Study
22. 2058 POSTER Factors influencing survival of 107 HER2 positive breast cancer patients treated with trastuzumab based neoadjuvant chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.